0
May 22, 1972, Vol 220, No. 8 >
ARTICLE | May 22, 1972

Some Recollections of the Meningococcal Diseases: Title and subTitle BreakThe First Harry F. Dowling Lecture FREE

Harry A. Feldman, MD
[+] Author Affiliations

Read as the First Harry F. Dowling Lecture, Chicago, April 29, 1971.

Reprint requests to 750 E Adams St, Syracuse 13210 (Dr. Feldman).


JAMA. 1972;220(8):1107-1112. doi:10.1001/jama.1972.03200080049012
Text Size: A A A
Published online
Article
References

I would be less than truthful were I to deny that I approached this assignment with anything but considerable trepidation. For one, this being the first Harry F. Dowling Lecture means that it should set the tone for those which follow. That Harry Dowling is here makes the occasion truly enjoyable but unavoidably adds to the usual anxieties of the student who wishes to perform well in the presence of his teacher. In our case, this relationship covers a span of almost 35 years. Should I succumb to the temptation to "tell it like it was" by substituting reminiscence for fact, then perhaps you will be charitable and will seek and find some purpose in such deviations.

I first met Harry Dowling in 1936. At that time, I was a medical student at the George Washington University School of Medicine, working in John Hanks's laboratory in the department of bacteriology.

REFERENCES

1 +
Dowling HF, Dauer CC, Feldman HA, et al:  Pneumococcal meningitis . New Eng J Med 226:1015-1018, 1942;.
2 +
Feldman HA, Sweet LK, Dowling HF:  Sulfadiazine therapy of purulent meningitis . War Med 2:995-1007, 1942;.
3 +
Kuhns DM, Feldman HA:  Laboratory methods used in determining the value of sulfadiazine as a mass prophylactic against meningococcic infections . Amer J Public Health 33:1461-1465, 1943;.
4 +
Thomas HM Jr:  Meningococcic meningitis and septicemia . JAMA 123:264-272, 1943;.
5 +
Kuhns DM, Nelson CT, Feldman HA, et al:  The prophylactic value of sulfadiazine . JAMA 123:335-339, 1943;.
6 +
Lepper MH, Sweet LK, Dowling HF:  The treatment of meningococcic infections with sulfadiazine and sulfamerazine . JAMA 123:134-138, 1943;.
7 +
Sweet LK, Dumoff-Stanley E, Dowling HF:  Meningococcic meningitis treated with sulfadiazine and sulfamerazine: A three-year study . Ann Intern Med 23:338-348, 1945;.
8 +
Mayer RL, Dowling HF:  The determination of meningococcic antibodies by a centrifuge-agglutination test . J Immun 51:349-354, 1945;.
9 +
Dowling HF, Mayer RL, Sweet LK, et al:  A study of the agglutinin response in patients with meningococcic meningitis . J Clin Invest 24:160-164, 1945;.
10 +
Dowling HF: The Acute Bacterial Diseases . Philadelphia, WB Saunders Co, 1948;, p 225.
11 +
Schoenbach EB, Phair JJ:  The sensitivity of meningococci to sulfadiazine . Amer J Hyg 47:177-186, 1948;.
12 +
Love BD, Finland M:  In vitro susceptibility of meningococci to eleven antibiotics and sulfadiazine . Amer J Med Sci 228:534-539, 1954;.
13 +
Lepper MH, Dowling HF:  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin . Arch Intern Med 88:489-494, 1951;.
14 +
Lepper MH, Dowling HF, Wehrle PF, et al:  Meningococcic meningitis: Treatment with large doses of penicillin compared to treatment with gantrisin . J Lab Clin Med 40:891-900, 1952;.
15 +
Greenfield S, Sheehe PR, Feldman HA:  Meningococcal carriage in a population of "normal" families . J Infect Dis 123:67-73, 1971;.
16 +
Greenfield S, Feldman HA:  Familial carriers and meningococcal meningitis . New Eng J Med 277:497-502, 1967;.
17 +
Deal WB, Saunders E:  Efficacy of rifampin in treatment of meningococcal carriers . New Eng J Med 281:641-645, 1969;.
18 +
Devine LF, Johnson DP, Hagerman CR, et al:  Rifampin: levels in serum and saliva and effect on the meningococcal carrier state . JAMA 214:1055-1059, 1970;.
19 +
Eickhoff TC:  In vitro and in vivo studies of resistance to rifampin in meningococci . J Infect Dis 123:414-420, 1971;.
20 +
Gotschlich EC, Liu TY, Artenstein MS:  Human immunity to the meningococcus: III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides . J Exp Med 129:1349-1365, 1969;.
21 +
Gotschlich EC, Goldschneider I, Artenstein MS:  Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers . J Exp Med 129:1367-1384, 1969;.
22 +
Artenstein MS, Gold R, Zimmerly JG, et al:  Prevention of meningococcal disease by group C polysaccharide vaccine . New Eng J Med 282:417-420, 1970;.
23 +
 Meningococcal disease—United States, epidemiologic year 1970 . Morbidity Mortality Weekly Rep 19:414-415, 1970;.
24 +
 Annual Supplement, 1969 . Morbidity Mortality Weekly Rep p 45, 1969;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Dowling HF, Dauer CC, Feldman HA, et al:  Pneumococcal meningitis . New Eng J Med 226:1015-1018, 1942;.
2 +
Feldman HA, Sweet LK, Dowling HF:  Sulfadiazine therapy of purulent meningitis . War Med 2:995-1007, 1942;.
3 +
Kuhns DM, Feldman HA:  Laboratory methods used in determining the value of sulfadiazine as a mass prophylactic against meningococcic infections . Amer J Public Health 33:1461-1465, 1943;.
4 +
Thomas HM Jr:  Meningococcic meningitis and septicemia . JAMA 123:264-272, 1943;.
5 +
Kuhns DM, Nelson CT, Feldman HA, et al:  The prophylactic value of sulfadiazine . JAMA 123:335-339, 1943;.
6 +
Lepper MH, Sweet LK, Dowling HF:  The treatment of meningococcic infections with sulfadiazine and sulfamerazine . JAMA 123:134-138, 1943;.
7 +
Sweet LK, Dumoff-Stanley E, Dowling HF:  Meningococcic meningitis treated with sulfadiazine and sulfamerazine: A three-year study . Ann Intern Med 23:338-348, 1945;.
8 +
Mayer RL, Dowling HF:  The determination of meningococcic antibodies by a centrifuge-agglutination test . J Immun 51:349-354, 1945;.
9 +
Dowling HF, Mayer RL, Sweet LK, et al:  A study of the agglutinin response in patients with meningococcic meningitis . J Clin Invest 24:160-164, 1945;.
10 +
Dowling HF: The Acute Bacterial Diseases . Philadelphia, WB Saunders Co, 1948;, p 225.
11 +
Schoenbach EB, Phair JJ:  The sensitivity of meningococci to sulfadiazine . Amer J Hyg 47:177-186, 1948;.
12 +
Love BD, Finland M:  In vitro susceptibility of meningococci to eleven antibiotics and sulfadiazine . Amer J Med Sci 228:534-539, 1954;.
13 +
Lepper MH, Dowling HF:  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin . Arch Intern Med 88:489-494, 1951;.
14 +
Lepper MH, Dowling HF, Wehrle PF, et al:  Meningococcic meningitis: Treatment with large doses of penicillin compared to treatment with gantrisin . J Lab Clin Med 40:891-900, 1952;.
15 +
Greenfield S, Sheehe PR, Feldman HA:  Meningococcal carriage in a population of "normal" families . J Infect Dis 123:67-73, 1971;.
16 +
Greenfield S, Feldman HA:  Familial carriers and meningococcal meningitis . New Eng J Med 277:497-502, 1967;.
17 +
Deal WB, Saunders E:  Efficacy of rifampin in treatment of meningococcal carriers . New Eng J Med 281:641-645, 1969;.
18 +
Devine LF, Johnson DP, Hagerman CR, et al:  Rifampin: levels in serum and saliva and effect on the meningococcal carrier state . JAMA 214:1055-1059, 1970;.
19 +
Eickhoff TC:  In vitro and in vivo studies of resistance to rifampin in meningococci . J Infect Dis 123:414-420, 1971;.
20 +
Gotschlich EC, Liu TY, Artenstein MS:  Human immunity to the meningococcus: III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides . J Exp Med 129:1349-1365, 1969;.
21 +
Gotschlich EC, Goldschneider I, Artenstein MS:  Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers . J Exp Med 129:1367-1384, 1969;.
22 +
Artenstein MS, Gold R, Zimmerly JG, et al:  Prevention of meningococcal disease by group C polysaccharide vaccine . New Eng J Med 282:417-420, 1970;.
23 +
 Meningococcal disease—United States, epidemiologic year 1970 . Morbidity Mortality Weekly Rep 19:414-415, 1970;.
24 +
 Annual Supplement, 1969 . Morbidity Mortality Weekly Rep p 45, 1969;.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems